Hirva Mamdani1, Thomas Birdas2, Shadia I Jalal3. 1. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA. 2. Department of Surgery, Thoracic Division, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA. 3. Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA.
Abstract
BACKGROUND: Concurrent chemoradiation (CRT) followed by surgery is a standard of care for locally advanced esophageal adenocarcinoma. It remains unclear if surgery following CRT offers any meaningful survival benefit compared to CRT alone in patients with clinical N3 disease who are at the highest risk of developing distant disease relapse. METHODS: We conducted analysis of the National Cancer Database (NCDB) to compare overall survival (OS) of patients with locally advanced esophageal adenocarcinoma (cTanyN1-3M0 based on AJCC 7th staging system) who underwent CRT with or without surgery and analyzed outcomes based on the cN stage. RESULTS: 7,520 patients were included in the analysis-74.7% had cN1 disease, 21.1% had cN2 disease, and 4.3% had cN3 disease. The median OS advantage offered by CRT followed by surgery was 22, 15.8, and 9.6 months compared to CRT alone in cN1, cN2, and cN3 patients, respectively. The 5-year OS estimates in the surgical group were 36.9%, 31.6% and 15.9% in cN1, cN2 and cN3 groups, respectively. CONCLUSIONS: Surgery following CRT in patients with locally advanced esophageal adenocarcinoma leads to improvement in OS, with the largest benefit noted in patients with cN1 and cN2 disease. Surgery following CRT also confers meaningful long-term survival advantage for a subset of cN3 patients. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Concurrent chemoradiation (CRT) followed by surgery is a standard of care for locally advanced esophageal adenocarcinoma. It remains unclear if surgery following CRT offers any meaningful survival benefit compared to CRT alone in patients with clinical N3 disease who are at the highest risk of developing distant disease relapse. METHODS: We conducted analysis of the National Cancer Database (NCDB) to compare overall survival (OS) of patients with locally advanced esophageal adenocarcinoma (cTanyN1-3M0 based on AJCC 7th staging system) who underwent CRT with or without surgery and analyzed outcomes based on the cN stage. RESULTS: 7,520 patients were included in the analysis-74.7% had cN1 disease, 21.1% had cN2 disease, and 4.3% had cN3 disease. The median OS advantage offered by CRT followed by surgery was 22, 15.8, and 9.6 months compared to CRT alone in cN1, cN2, and cN3 patients, respectively. The 5-year OS estimates in the surgical group were 36.9%, 31.6% and 15.9% in cN1, cN2 and cN3 groups, respectively. CONCLUSIONS: Surgery following CRT in patients with locally advanced esophageal adenocarcinoma leads to improvement in OS, with the largest benefit noted in patients with cN1 and cN2 disease. Surgery following CRT also confers meaningful long-term survival advantage for a subset of cN3 patients. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Esophageal adenocarcinoma; N3 disease; National Cancer Database (NCDB); esophagectomy; lymph node staging
Authors: Kenneth A Kesler; Paul R Helft; Elizabeth A Werner; Neel P Jain; Jo Ann Brooks; John M DeWitt; Julia K Leblanc; Naomi S Fineberg; Lawrence H Einhorn; John W Brown Journal: Ann Thorac Surg Date: 2005-04 Impact factor: 4.330
Authors: Jae Y Kim; Arlene M Correa; Ara A Vaporciyan; Jack A Roth; Reza J Mehran; Garrett L Walsh; David C Rice; Jaffer A Ajani; Dipen M Maru; Manoop S Bhutani; James Welsh; Edith M Marom; Stephen G Swisher; Wayne L Hofstetter Journal: Ann Thorac Surg Date: 2011-10-01 Impact factor: 4.330
Authors: Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245
Authors: Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast Journal: Lancet Oncol Date: 2015-08-05 Impact factor: 41.316
Authors: Dean Bogoevski; Florian Onken; Alexandra Koenig; Jussuf T Kaifi; Paulus Schurr; Guido Sauter; Jakob R Izbicki; Emre F Yekebas Journal: Ann Surg Date: 2008-04 Impact factor: 12.969
Authors: Ronan J Kelly; Jaffer A Ajani; Jaroslaw Kuzdzal; Thomas Zander; Eric Van Cutsem; Guillaume Piessen; Guillermo Mendez; Josephine Feliciano; Satoru Motoyama; Astrid Lièvre; Hope Uronis; Elena Elimova; Cecile Grootscholten; Karen Geboes; Syed Zafar; Stephanie Snow; Andrew H Ko; Kynan Feeney; Michael Schenker; Piotr Kocon; Jenny Zhang; Lili Zhu; Ming Lei; Prianka Singh; Kaoru Kondo; James M Cleary; Markus Moehler Journal: N Engl J Med Date: 2021-04-01 Impact factor: 91.245
Authors: Hirva Mamdani; Bryan Schneider; Susan M Perkins; Heather N Burney; Pashtoon Murtaza Kasi; Laith I Abushahin; Thomas Birdas; Kenneth Kesler; Tracy M Watkins; Sunil S Badve; Milan Radovich; Shadia I Jalal Journal: Front Oncol Date: 2021-09-17 Impact factor: 6.244